{"id":36825,"date":"2025-07-07T14:43:53","date_gmt":"2025-07-07T06:43:53","guid":{"rendered":"https:\/\/flcube.com\/?p=36825"},"modified":"2025-07-07T14:43:54","modified_gmt":"2025-07-07T06:43:54","slug":"scg-cell-therapy-obtains-nmpa-approval-for-scg101v-in-chronic-hbv-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36825","title":{"rendered":"SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study"},"content":{"rendered":"\n<p>China\u2019s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG Cell Therapy Pte. Ltd, a Singapore-based company with an office in Shanghai, to conduct a Phase I\/II study for its SCG101V. This HBV-specific TCR-engineered T cell therapy is the world&#8217;s first of its kind to receive approval for study in chronic hepatitis B virus (HBV) infection.<\/p>\n\n\n\n<p><strong>Mechanism of Action<\/strong><br>Developed using SCG&#8217;s proprietary GianTCR platform, SCG101V utilizes HBV-specific T cell receptors to selectively identify and target HBV-infected hepatocytes. The therapy works through multiple mechanisms to eliminate covalently closed circular DNA (cccDNA), eradicate viral reservoirs and integrated fragments, and establish protective immune memory. This approach aims to completely remove viral reservoirs, potentially offering a path to a functional cure with no viral rebound.<\/p>\n\n\n\n<p><strong>Clinical Data and Efficacy<\/strong><br>The approval follows SCG&#8217;s recent presentation at EASL 2025, where updated clinical data from its Late-Breaker session demonstrated dual antiviral and antitumor efficacy in HBV-related hepatocellular carcinoma patients. Specifically, 94% of patients achieved a 1.0-4.6 log10 reduction in HBsAg within 28 days, and 23.5% attained complete HBsAg clearance within 21 days, with sustained results for 1 year without rebound.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2019s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG&#8230;<\/p>\n","protected":false},"author":1,"featured_media":36826,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[77,62,582,89],"class_list":["post-36825","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-scg-cell-therapy","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG Cell Therapy Pte. Ltd, a Singapore-based company with an office in Shanghai, to conduct a Phase I\/II study for its SCG101V. This HBV-specific TCR-engineered T cell therapy is the world&#039;s first of its kind to receive approval for study in chronic hepatitis B virus (HBV) infection.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36825\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study\" \/>\n<meta property=\"og:description\" content=\"China\u2019s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG Cell Therapy Pte. Ltd, a Singapore-based company with an office in Shanghai, to conduct a Phase I\/II study for its SCG101V. This HBV-specific TCR-engineered T cell therapy is the world&#039;s first of its kind to receive approval for study in chronic hepatitis B virus (HBV) infection.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36825\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-07T06:43:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-07T06:43:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0708.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36825#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36825\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study\",\"datePublished\":\"2025-07-07T06:43:53+00:00\",\"dateModified\":\"2025-07-07T06:43:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36825\"},\"wordCount\":208,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36825#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0708.webp\",\"keywords\":[\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"SCG Cell Therapy\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36825#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36825\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36825\",\"name\":\"SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36825#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36825#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0708.webp\",\"datePublished\":\"2025-07-07T06:43:53+00:00\",\"dateModified\":\"2025-07-07T06:43:54+00:00\",\"description\":\"China\u2019s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG Cell Therapy Pte. Ltd, a Singapore-based company with an office in Shanghai, to conduct a Phase I\\\/II study for its SCG101V. This HBV-specific TCR-engineered T cell therapy is the world's first of its kind to receive approval for study in chronic hepatitis B virus (HBV) infection.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36825#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36825\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36825#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0708.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0708.webp\",\"width\":1080,\"height\":608,\"caption\":\"SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36825#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG Cell Therapy Pte. Ltd, a Singapore-based company with an office in Shanghai, to conduct a Phase I\/II study for its SCG101V. This HBV-specific TCR-engineered T cell therapy is the world's first of its kind to receive approval for study in chronic hepatitis B virus (HBV) infection.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36825","og_locale":"en_US","og_type":"article","og_title":"SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study","og_description":"China\u2019s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG Cell Therapy Pte. Ltd, a Singapore-based company with an office in Shanghai, to conduct a Phase I\/II study for its SCG101V. This HBV-specific TCR-engineered T cell therapy is the world's first of its kind to receive approval for study in chronic hepatitis B virus (HBV) infection.","og_url":"https:\/\/flcube.com\/?p=36825","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-07T06:43:53+00:00","article_modified_time":"2025-07-07T06:43:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0708.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36825#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36825"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study","datePublished":"2025-07-07T06:43:53+00:00","dateModified":"2025-07-07T06:43:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36825"},"wordCount":208,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36825#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0708.webp","keywords":["Cell-therapy","Clinical trial approval \/ initiation","SCG Cell Therapy","Viral hepatitis"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36825#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36825","url":"https:\/\/flcube.com\/?p=36825","name":"SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36825#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36825#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0708.webp","datePublished":"2025-07-07T06:43:53+00:00","dateModified":"2025-07-07T06:43:54+00:00","description":"China\u2019s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG Cell Therapy Pte. Ltd, a Singapore-based company with an office in Shanghai, to conduct a Phase I\/II study for its SCG101V. This HBV-specific TCR-engineered T cell therapy is the world's first of its kind to receive approval for study in chronic hepatitis B virus (HBV) infection.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36825#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36825"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36825#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0708.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0708.webp","width":1080,"height":608,"caption":"SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36825#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0708.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36825"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36825\/revisions"}],"predecessor-version":[{"id":36827,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36825\/revisions\/36827"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36826"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}